Unknown

Dataset Information

0

Subcutaneous REGEN-COV Antibody Combination for Covid-19 Prevention.


ABSTRACT:

Background

Casirivimab and imdevimab (REGEN-COV™) markedly reduces risk of hospitalization or death in high-risk individuals with Covid-19. Here we explore the possibility that subcutaneous REGEN-COV prevents SARS-CoV-2 infection and subsequent Covid-19 in individuals at high risk of contracting SARS-CoV-2 by close exposure in a household with a documented SARS-CoV-2-infected individual.

Methods

Individuals ≥12 years were enrolled within 96 hours of a household contact being diagnosed with SARS-CoV-2 and randomized 1:1 to receive 1200 mg REGEN-COV or placebo via subcutaneous injection. The primary efficacy endpoint was the proportion of participants without evidence of infection (SARS-CoV-2 RT-qPCR- negative) or prior immunity (seronegative) who subsequently developed symptomatic SARS-CoV-2 infection during a 28-day efficacy assessment period.

Results

Subcutaneous REGEN-COV significantly prevented symptomatic SARS-CoV-2 infection compared with placebo (81.4% risk reduction; 11/753 [1.5%] vs. 59/752 [7.8%], respectively; P<0.0001), with 92.6% risk reduction after the first week (2/753 [0.3%] vs. 27/752 [3.6%], respectively). REGEN-COV also prevented overall infections, either symptomatic or asymptomatic (66.4% risk reduction). Among infected participants, the median time to resolution of symptoms was 2 weeks shorter with REGEN-COV vs. placebo (1.2 vs. 3.2 weeks, respectively), and the duration of time with high viral load (>10 4 copies/mL) was lower (0.4 vs. 1.3 weeks, respectively). REGEN-COV was generally well tolerated.

Conclusions

Administration of subcutaneous REGEN-COV prevented symptomatic Covid-19 and asymptomatic SARS-CoV-2 infection in uninfected household contacts of infected individuals. Among individuals who became infected, REGEN-COV reduced the duration of symptomatic disease, decreased maximal viral load, and reduced the duration of detectable virus. ( ClinicalTrials.gov number, NCT04452318 .).

SUBMITTER: O'Brien MP 

PROVIDER: S-EPMC8219114 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8362593 | biostudies-literature
| S-EPMC8219113 | biostudies-literature
| S-EPMC8522800 | biostudies-literature
| S-EPMC9344792 | biostudies-literature
| S-EPMC8179113 | biostudies-literature
| S-EPMC8755381 | biostudies-literature
| S-EPMC8425334 | biostudies-literature
| S-EPMC7461298 | biostudies-literature
| S-SCDT-EMM-2022-15904 | biostudies-other
| S-EPMC8808333 | biostudies-literature